Protein controlled release

Balkundi, S., Veerabadran, N., Lvov, Y. and Price, R. (2007) Protein Controlled Release from Halloysite Nanotubules. Journal of Controlled Release 90,766-771. 

Carrasquillo, K. G., Stanley, A. M., Aponte-Carro, J. C., DeJesus, P, Costantino, H. R., Bosques, C. J., and Griebenow, K. (2001), Non-aqueous encapsulation of excipient stabilized spray freeze dried BSA into poly(lactide-co-glycolide) microspheres results in release of native protein,/. Controlled Release,76,199-208. 

Keywords Proteins Controlled release Polymers Liposomes Microcrystals Pulmonary... 

Hassan C, Stewart J, Peppas N (2000) Diffusional characteristics of freeze/thawed poly(vinyl alcohol) hydrogels applications to protein controlled release from multilaminate devices. Eur J Pharm Biopharm 49 161-165... 

Quatemized chitosan-organic rectorite intercalated composites based NPs For protein controlled release [189]... 

Xu R, Xin S, Zhou X, Li W, Cao F, Feng X, Deng H. Quaternized chitosan-organic rectorite intercalated composites based nanoparticles for protein controlled release. Int J Pharm. 2012 438(l-2) 258-65. 

W.J. Lambert, and K.D. Peck, Development of an in situ forming biodegradable poly-lac-tide-co-glycolide system for the controlled release of proteins, /. Control. Release, 33, 189-195,1995. 

Van De Wetering, P, A. T. Metiers, R. G. Schoenmakers, and J. A. Hubbell. 2005. Poly(ethylene glycol) hydrogels formed by conjugate addition with controllable swelling, degradation, and release of pharmaceutically active proteins. / Control Release 102 619-27. 

Electrotransport technology offers a number of benefits for therapeutic appHcations, including systemic or local adininistration of a wide variety of therapeutic agents with the potential adininistration of peptides and proteins long-term noninvasive administration, improving convenience and compliance controlled release, providing a desired deflvery profile over an extended period with rapid onset of efficacious plasma dmg levels and in some cases reduced side effects and a transport rate relatively independent of skin type or site. Additional benefits include easy inception and discontinuation of treatment, patterned and feedback-controlled deflvery, and avoidance of first-pass hepatic metaboHsm. 

Bovine growth hormone, a difficult protein for which to develop controlled release systems due to its propensity toward self-aggregation and inactivation, has successfully been incorporated into polyanhydride matrices (18). The growth hormone was colyophilized with sucrose, dry-mixed with finely powdered polyanhydride, and then compression molded into 1.4-cm-diaraeter wafers, 1 mm thick. As is shown in Fig. 15, release of bovine growth hormone was well controlled over a prolonged period of time. The assay for bovine... 

Ethylene vinyl acetate has also found major applications in drug delivery. These copolymers used in drug release normally contain 30-50 wt% of vinyl acetate. They have been commercialized by the Alza Corporation for the delivery of pilocarpine over a one-week period (Ocusert) and the delivery of progesterone for over one year in the form of an intrauterine device (Progestasert). Ethylene vinyl acetate has also been evaluated for the release of macromolecules such as proteins. The release of proteins form these polymers is by a porous diffusion and the pore structure can be used to control the rate of release (3). Similar nonbiodegradable polymers such as the polyurethanes, polyethylenes, polytetrafluoroethylene and poly(methyl methacrylate) have also been used to deliver a variety of different pharmaceutical agents usually as implants or removal devices. 

As pharmaceutical scientists gain experience and tackle the primary challenges of developing stable parenteral formulations of proteins, the horizons continue to expand and novel delivery systems and alternative routes of administration are being sought. The interest in protein drug delivery is reflected by the wealth of literature that covers this topic [150-154]. Typically, protein therapeutics are prepared as sterile products for parenteral administration, but in the past several years, there has been increased interest in pulmonary, oral, transdermal, and controlled-release injectable formulations and many advances have been made. Some of the more promising recent developments are summarized in this section. 

D. Bodmer, T. Kissel, and E. Traechslin, Factors influencing the release of peptides and proteins from biodegradable parenteral depot systems, J. Controlled Release, 21, 129 (1992). 

DW Urry, CM Harris, CX Luan, CH Luan, C Gowda, TM Parker, SQ Peng, J Xu. Transductional protein-based polymers as new controlled-release vehicles. In K Park, ed. Controlled Drug Delivery Challenges and Strategies. Washington, DC ACS, 1997, pp 405-437. 

Lee, V. H., et al. Biopharmaceutics of transmucosal peptide and protein drug administration role of transport mechanisms with a focus on the involvement of PepTl. J. Control. Release 1999, 62, 129-140. 

Intestinal MDR transport proteins and P-450 enzymes as barriers to oral drug delivery, J. Controlled Release 1999, 62, 25-31. 

Bio-nanocomposites based on calcium phosphates can perform other innovative fundions such as acting as a reservoir for the controlled release of bioadive compounds once the material is implanted in the bone defect. For instance, the incorporation of a morphogenetic protein that promotes bone regeneration in an HAP-alginate-collagen system [110] or a vitamin in a Ca-deficient HAP-chitosan nanocomposite [111] are recent examples of this kind of application. 

Akiyoshi K, Kobayashi S, Shichibe S et al (1998) Self-assembled hydrogel nanoparticle of cholesterol-bearing pullulan as a carrier of protein drugs Complexation and stabilization of insulin. J Control Release 54 313-320... 

Leonard M, Boisseson MRD, Hubert P et al (2004) Hydrophobically modified alginate hydrogels as protein carriers with specific controlled release properties. J Control Release 98 395 105... 

Lin YH, Sonaje K, Lin KM et al (2008) Multi-ion-crosslinked nanoparticles with pH-responsive characteristics for oral delivery of protein drugs. J Control Release 132 141-149... 

Sah H (1999) Stabilization of proteins against methylene chloride/water interface induced denaturation and aggregation. J Control Release 58 143-151... 

Panyam J, Dali MM, Sahoo SK et al (2003) Polymer degradation and in vitro release of a model protein from poly(D, L-lactide-co-glycolide) nano- and microparticles. J Control Release 92 173-187... 

Akagi T, Kaneko T, Kida T et al (2005) Preparation and characterization of biodegradable nanoparticles based on poly(y-glutamic acid) with L-phenylalanine as a protein carrier. J Control Release 108 226-236... 

Ataman-Onal Y, Munier S, Ganee A et al (2006) Surfactant-free anionic PLA nanoparticles coated with HIV-1 p24 protein induced enhanced cellular and humoral immune responses in various animal models. J Control Release 112 175-185... 

Drug development, proteins in, 20 839 Drug discovery, yeasts in, 26 488 Drug dosage forms, 15 702-718 aerosols, IS 717 biotechnology and, IS 717-718 capsules, 15 708 granules, 15 702-705 liquid, 15 712-713 lyophilization, 15 716 ophthalmic, 15 716 parenteral, IS 713-716 prolonged action/controlled release solid, 15 708-712... 

---